VESO is a leading supplier and distributor of veterinary medicine in the Norwegian market, including aquaculture and terrestrial animals. The distribution of vaccines and pharmaceuticals takes place from the company's head office in Oslo; VESO Wholesaler and VESO Pharmacy. VESO Vikan and VESO Chile are aquatic research facilities that contract experimental challenge trials for the pharmaceutical-, feed- and breeding industries, research institutes and government agencies. Trials can be conducted according to GMP, GLP and GCP quality standards. The aim of the company is to contribute to improved fish and animal health by providing vaccines and pharmaceuticals, as well as services related to documentation of the efficacy and safety of the products. The company represents an independent research partner, and strives to maintain the highest scientific competence and integrity. VESO was established in 1988. The Norwegian state owns 34 percent of the shares in VESO. The other shares are owned by AquaNova Invest AS (61.3 per cent) and by 18 employees and former employees (4.7 per cent). VESO is a majority shareholder of Brynsløkken AS who produce antifouling products for the aquaculture industry.